Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib as Adjuvant Therapy After Nephrectomy in RCC
DRKS00003892Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Pazopanib with Placebo (2 arms). Started Apr 2012; status: active, not recruiting.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on DRKS00003892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003892.